Antibiotic compounds from Bacillus: why are they so amazing by Fickers, Patrick
American Journal of Biochemistry and Biotechnology 8 (1): 38-43, 2012 
ISSN 1553-3468 
© 2012 Science Publications 
38 
 
Antibiotic Compounds from Bacillus: Why are they so Amazing? 
 
Patrick Fickers  
Unit of Biotechnology and Bioprocess, 
Universite libre de Bruxelles, Av. F.-D. Roosevelt 50, 
CP165/61 B-1050 Brussels, Belgium 
 
Abstract: The constant increase of multi-drug resistant pathogens stimulates research, more than ever, 
to identify and develop new antibacterial compounds. The recent advances in genome sequencing have 
highlighted the genus Bacillus as an unexpected source of antibiotic-like compounds. This review 
focus on the different class of antimicrobial molecules produce by Bacillus genus such as polyketides, 
nonribosomal peptide, bacteriocins as well as other unusual peptides. 
 




 The discovery of penicillin by A. Fleming more 
than 90 years ago has revolutionized the medicine and 
allowed to treat millions of people from bacterial 
infections. Unfortunately, the intensive use and misuse 
of antibiotics have generated a strong selective pressure 
for the emergence of resistant strains. Actually, the 
constant increase of multi-drug resistant pathogenic 
microorganisms stim ulates more than ever effort to 
identify and develop new antibacterial compounds. In 
that field, the recent advances in genome sequencing 
have highlighted the genus Bacillus as an unexpected 
source of antibiotic-like compounds. Indeed, for some 
of them, such as Bacillus subtilis, more than 4% of the 
genome has been found potentially devoted to the 
synthesis of Polyketides (PKs), Nonribosomal Peptide 
(NRPs), bacteriocins as well as other unusual 
antibiotics (Kunst et al., 1997; Chen et al., 2009a; 
Arguelles-Arias et al., 2009). In the past, these 
compounds had to be identified by intensive screening 
for antimicrobial activity against appropriate targets and 
subsequently purified using fastidious methods prior to 
assess their potential utilization as antibacterial or 
antifungal compound. However, since the advent of the 
genomic era, available bacterial genomes are screened 
for bacteriocin, Polyketide Synthetase (PKS) and 
Nonribosomal Peptide-Synthetase (NRPS) gene clusters 
using appropriate bioinformatics tools, rendering the 
identification of new compounds more easy-going 
(Tapi et al., 2010; Caboche et al., 2008). 
 
Polyketides and non-ribosomal peptide: Polyketides 
(PKs) and Nonribosomal Peptides (NRPs) are 
synthesized by large multimodular synthetase by 
elongation of activated monomers of amino and 
hydroxyl acid building blocks. The genes coding for 
these synthetases are clustered in operons than can span 
over 150 kb. NRPSs are organized in modules 
responsible for the incorporation of a specific amino 
acid. The modules consist of three main core domains 
that catalyze a specific reaction for the incorporation of 
a monomer. Firstly, the adenylation domain (A) selects 
and activates the cognate amino acid as an amino acyl-
adenylate. Then after, Thiolation domain (T) covalently 
binds the activated monomer to the synthetase through 
a phosphopantetheinyl arm. Finaly, the condensation 
domain (C) catalyses the formation of the peptide 
linkage between the activated amino acids from two 
adjacent T modules. Two additional specific modules 
are also requested for NRPs synthesis. These are the 
loading module, composed only by one A and T 
domain, involved in the activation and incorporation of 
the first amino-acid of the NRP and a termination 
module containing a Thioesterase (TE) domain, which 
releases the newly synthetized peptide from the 
synthetase. Beside these three main domains, many 
NRPSs feature more specialized domains within 
modules that allow residue modifications, namely 
Epimerisation (E), Methylation (M), Oxidation (Ox), 
Reduction (R), Formylation (F) and Heterocyclisation 
(Cy). These specialized domains enable NRPSs to 
synthesize an impressive number of diversified 
structures with broad range of biological activities that 
could not be obtained by the ribosomal machinery 
(Felnagle et al., 2008). This diversity of structure is 
responsible for their board-range of biological 
activities, targets, mechanisms of action, allowing their 
exploitation by the biopharmaceutical industry. 
Bacitracin, for instance, used in human medicine, 
inhibit the biosynthesis of the bacterial cell wall by 
interacting with undecaprenyl pyrophosphate, involved 
in peptidoglycan synthesis (Stone and Strominger, 
1971). Since its US FDA approval in 2010, bacitracin is 
used for the treatment of infants with staphylococcal 
pneumonia and empyema. Mechanistically, NRPS 
could function based on two distinct schemes. Linear 
NRPSs proceed synthesis starting with the loading 
module, following by addition of specific amino acid 
according the ordered fashion of the different modules 
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in the synthetase and ending with the cleavage of the 
peptide from the synthetase by the TE domain. Iterative 
NRPSs use successively, one, several or the entire set 
of modules constituting the synthetases (Mootz et al., 
2002). Since the discovery of gramicidin from B. 
brevis, the first NRP compound characterized in the 
early ’70, many bioactive NRPs have been isolated and 
their biosynthetic clusters characterized. Recently, the 
Norine database containing hundreds of NRPS 
molecules has been created, providing users with an 
interesting computational tool for systematic study of 
these molecules (Caboche et al., 2008). With 
emergence of powerful bioinformatics and molecular 
tools, identifying new metabolites by genome mining 
has become a reality (Ansari et al., 2004; Lanen and 
Shen, 2006). For instance, a bioinformatics analysis of 
the genome of B. thuringiensis led to the prediction of an 
NRPS constituted of seven modules that could be involved 
in the synthesis of a heptalipopeptide similar to kurstakin 
(Abderrahmani et al., 2011). The discovery of new natural 
products by genome mining is an encouraging sign, 
suggesting that this methodology could lead to the 
isolation of novel molecules of pharmacological interest.  
 PKSs assemble the core structure of polyketides 
from acyl-Coenzyme A (acyl-CoA) monomers in a 
head-to-tail fashion (Jenke-Kodama and Dittmann, 
2009; Hertweck et al., 2007). Type I PKSs are similar 
to NRPSs in that the different catalytic domains are 
found in a single polypeptide and are further subdivided 
into iterative and modular synthases. An iterative type I 
PKS is a monomodular synthase in which a single set of 
catalytic domains is used repeatedly in a highly 
programmed fashion. By contrast, modular PKSs 
feature several separate modules that do not repeat. 
Type II PKSs possess a biosynthetic mechanism 
analogous to iterative type I PKSs but harbour their 
catalytic domains on mono-or bi-functional proteins 
(Hertweck et al., 2007). Several bacteria, including B. 
subtilis and fungi, but mostly plants, possess type III 
PKSs (Nakano et al., 2009; Resmi and Soniya, 2012; Li 
et al., 2011). They consist of a single multimodular 
protein synthesizing molecules devoid of any 
antibimicrobial activities (Felnagle et al., 2008). Each 
PKS module is composed by at least three core 
domains: an Acyltransferase Domain (AT) which 
selects the appropriate monomers, an acyl Carrier 
Protein Domain (ACP) that carry the activated 
monomer through the formation of a thioester linkage 
and a Ketosynthase (KS) domain responsible for the 
condensation between the activated monomer and the 
polyketide intermediate present on two adjacent ACP 
domains. Additional secondary domains such as 
Ketoreductase (KR), Oxidation (Ox), Dehydratase 
(DH), Methyltransferase (MT), Enoylreductase (ER) 
and Methylation (M) domains are involved in the 
chemical modification of the growing polyketide. Type 
II PKSs often feature a Cyclase (Cy) domain leading to 
the formation of aromatic structures. Similarly to 
NRPS, the last module contains a Thioesterase (TE) 
domain that catalyzes the release of the final product 
from the enzyme (Meurer et al., 1997). Due to their 
versatile assemblage mechanism, polyketides exhibit 
remarkable diversity both in terms of structure and 
biological activities. For instance, three functional gene 
clusters directing the synthesis of difficidin, 
macrolactin and bacillaene were identified in B. 
amyloliquefaciens (Arguelles-Arias et al., 2009; Chen 
et al., 2007). Difficidin is an unsaturated 22-membered 
macrocylic polyene lactone phosphate ester with broad-
spectrum antibacterial activity (Wilson et al., 1987; 
Zimmerman et al., 1987). It inhibits protein 
biosynthesis and was recently shown promising in its 
suppressive action against Erwinia amylovara, a 
devasting plant pathogen causing necrotrophic fire 
blight disease of apple, pear and other rosaceous plants 
(Zweerink and Edison, 1987; Chen et al., 2009b). By 
contrast, macrolactin and bacillaene have not yet been 
demonstrated to be directly related to biocontrol, 
although they are both antimicrobial agents that could 
be potentially useful in human medicine. Macrolactin, 
which consists of a 24-membered ring lactone, had the 
ability to inhibit murine melanoma cancer cells as well 
as mammalian herpes simplex viruses. It was also 
shown effective in protecting lymphoblast cells from 
HIV (Gustafson et al., 1989). Similarly to difficidin, 
bacillaene is an inhibitor of prokaryotic protein 
synthesis constituted by an open-chain enamine acid 
with an extended polyene system. This compound 
displays antimicrobial activity toward human pathogens 
such as Serratia marcescens, Klebsiella pneumoniae 
and Staphylococcus aureus (Patel et al., 1995). 
 
NRPS/PKS hybrid synthetases: Several compounds 
isolated from bacteria are synthesized by NRPS/PKS 
hybrid synthetases. These metabolites are composed of 
a polyketide backbone featuring incorporated amino 
acids in the case of a PKS-NRPS hybrid or a peptidyl 
chain harbouring ketone group characteristic of an 
NRPS-PKS hybrid. Among them are the three iturin 
lipopeptides, namely mycosubtilin (Duitman et al., 
1999), iturin A (Tsuge et al., 2001) and bacillomycin D 
(Hofemeister et al., 2004), produced by different strain 
of Bacillus. Iturins are amphiphilic cyclic peptides 
composed of seven α-amino acids linked to a single β-
amino fatty acid. The length of the fatty acid moiety 
may vary from C14 to C17 and different homologous 
compounds with a linear or branched fatty acid moiety 
are usually co-produced (Hofemeister et al., 2004). This 
amphiphilic structure confers interesting biological 
properties to these secondary metabolites. For instance, 
mycosubtilin, produced by B. subtlis ATCC6633, was 
found very effective against the human pathogenic 
Am. J. Biochem. & Biotech., 8 (1): 38-43, 2012 
 
40 
yeast Candida albicans (Fickers et al., 2008; 2009) and 
as biocontrol agent to prevent Pythium infections of 
tomato seedlings (Leclere et al., 2005). The gene 
clusters involved in mycosubtilin is composed of one 
operon that span over 38 kb. It consists of four ORFs, 
designated fenF, mycA, mycB and mycC. The 
mycosubtilin synthetase reveals features unique for 
peptide synthetases as well as for fatty acid synthases. 
MycA subunit combines functional domains derived 
from peptide synthetases, amino transferases and fatty 
acid synthases. The growing understanding of PKS and 
NRPS mechanisms has led to the development of 
genetic engineering technique yielding to the synthesis 
of “synthetic” compounds. These methods consist of 
adding, subtracting or permuting modules or catalytic 
domains of a known natural synthase to obtain NRPs 
and PKs presenting modified structures and functions 
(Cane et al., 1998).  
 
Bacteriocin: Beside NRP and PK molecules, Bacillus 
genus is also able to produce interesting ribosomally 
synthetised peptides, the so-called bacteriocin (Lee and 
Kim, 2011; Abriouel et al., 2011). Based on their 
structure and biological activities, bacteriocins could be 
divided into three main groups. Class I bacteriocins, the 
so-called lantibiotics, are characterized by their unusual 
amino acids such as Lanthionine (Lan), 
Methyllanthionine (MeLAn) and dehydrated residues. 
Lan and MeLan are enzymatically synthesized by the 
cyclisation of a free cysteine and a dehydrated residue, 
namely Dehydroalanine (Dha) and didehydrobutyrine 
(Dhb), respectively. DhA and Dhb are obtained by the 
dehydratation of a serine or a threonine (McAuliffe et 
al., 2001). Lantibiotics can be further subdivided into 
two types based on their structure and mode of 
posttranslational modifications. Type A lantibiotics 
exhibit linear secondary structures and are positively 
charged. Two distinct LanB and LanC enzymes are 
involved in their post-translational modification and 
they are processed by a LanP protease. By contrast, 
Type B lantibiotics, exhibit a globular structure and are 
non-charged. They are modified by a single LanM 
enzyme and processed by a LanT transporter with N-
terminal-associated protease activity (Willey and Donk, 
2007). Beside this, two-component lantibiotics, 
consisting of a two peptides system that acts 
synergistically were also reported. Since a single LanM 
enzyme modifies these peptides, they were classified as 
type B lantibiotics (Asaduzzaman and Sonomoto, 
2009). Compared to lantibiotics, class II bacteriocins 
are non-modified peptides that are synthesized 
ribosomally. They are characterized by a molecular 
weigh below 5 kDa. They could be further subdivided 
into three subclasses (IIa, IIb, IIc) based on structural 
properties, activity and mode of action (Nes and Tagg, 
1996; Klaenhammer, 1993). Class IIa bacteriocins are 
characterized by an hydrophobic N-termini containing 
the YGNGV consensus sequence and a disulfide bridge. 
Class IIb feature two-component non-modified 
bacteriocin whereas class IIc regroups all the other 
molecules that do not correspond to class IIa and IIb. 
Class III bacteriocins are heat sensitive molecules with 
a molecular weight higher than 30 kDa. Its only 
representative among the Bacillus genera is the 
megacin A-216 produced by B. megaterium that only 
exhibits a phospholipase A2 activity (Tersch and 
Carlton, 1984). The type IA bacteriocin subtilin, 
produced by B. subtilis ATCC6633, is the model 
lantibiotic produced by members of the Bacillus genus. 
Active subtilin contains eight post-transcriptionally 
modified residues: four methyllanthionines (Abu-S-
Ala), one didehydrobutyrine, one dehydroalanine and 
one lanthionine (Ala-S-Ala) and one D-alanine 
(Banerjee and Hansen, 1988). Despite their relative 
variability of structure, lantibiotics share in common 
some characteristic features concerning their mode of 
synthesis. The gene cluster involved in their synthesis, 
which is approximately 10-15 kb, is composed of a 
structural gene as well as other genes necessary for the 
modification, transport, regulation and immunity of the 
producer strain. The subtilin biosyntheric gene cluster is 
composed of 10 ORFs, namely spaBTCSIFEGRK, 
forming four distinct operons (spaBTC, spaS, spaIFEG, 
spaRK). SpaS encodes a premature and inactive peptide 
of 56 residues with a 24 residues signal sequence. SpaB 
and SpaC are involved in the dehydratation of serine 
and threonine, which are required for the formation of 
Dha and Dhb, respectively, as well as that of 
lanthionine, which is the result of the cyclisation of Dha 
with thiol group of a free cysteine. Presubtilin is 
exported by the ABC type transporter protein SpaT and 
is then processed by the serine protease subtilisin to 
form a bioactive subtilin. Self-protection of the 
producer strain from the synthesized lantibiotics is 
ensured by different immunity mechanisms. The 
protein SpaI, a membrane-bound protein, interacts 
specifically with subtilin causing its inactivation. 
Beside this, the immunity complex formed by SpaF, 
SpaE and SpaG proteins pumps subtilin out of the 
producer strain. The production of lantibiotic is 
regulated at the transcriptional level in a cell-density-
dependent manner. It was evidenced that some 
lantibiotic, such as subtilin, can act as auto-inducing 
peptides (Kleerebezem et al., 2004). Two proteins, 
spaR and spaK, corresponding to a response regulator 
protein and a sensor kinase, respectively, form the 
regulatory system. After subtilin concentration in the 
culture medium reaches a certain threshold, it activates 
the membrane-bound SpaK protein which then 
autophosphorylates. This leads to the phosphorylation 
of SpaR, which in phosphorylated form can recognize 
the binding domain on three promoters upstream of 
Am. J. Biochem. & Biotech., 8 (1): 38-43, 2012 
 
41 
spaS, spaBTC and spaIFEG, resulting in subtilin 
production. In addition, SpaRK expression is controlled 
by the sporulation transcription factor sigma H (Stein et 
al., 2002). All of these highlight that lantibiotics 
synthesis is correlated to both to cell density and to 
sporulation mechanism. The biological activity of 
lantibiotics is centered on Gram-positive bacteria and 
consists of pores formation in target cell membranes 
and/or inhibition of peptidoglycane synthesis by 
interacting with undecaprenylpyrophosphoryl-
MurNAc-(pentapeptide)-GlcNAc, the so-called lipid II 
(McAuliffe et al., 2001; Bierbaum and Sahl, 2009). For 
some lantibiotics, such as epidermin, lipid II serve as a 
docking molecule that facilitate the pore formation 
(Parisot et al., 2008; Brotz and Sahl, 2000). 
 
Unusual peptide: Bacillus sp were also found able to 
synthetize others unusual antibiotic peptides. Among 
them, rhizocticins are phosphonate oligopeptide 
antibiotics containing the C-terminal nonproteinogenic 
amino acid (Z)-l-2-Amino-5-Phosphono-3-Pentenoic 
Acid (APPA) (Borisova et al., 2010; Kino, 2010; Kino 
et al., 2009). The molecules are synthesized by the so-
called L-amino acid ligase. These enzymes are able to 
catalyze the formation of an alpha-peptide bond from 
L-amino acids in an ATP-dependent manner. For 
instance, YwfE from B. subtilis 168, was the first 
reported L-amino acid ligase able to synthesizes various 
dipeptides (Tabata et al., 2005). Rhizocticin A, is 
known to inhibit the growth of yeast and filamentous 
fungi but is not active against bacteria. Rhizocticins 
enters the target cell via the oligopeptide transport 
system and must be cleaved by a peptidase in order to 
release the active APPA, which inhibit threonine 
synthase, an enzyme that catalyse the Pyridoxal 5’-
Phosphate (PLP)-dependent conversion of 
phosphohomoserine to L-threonine (Kino et al., 2009; 
Laber et al., 1994; Diddens et al., 1979). Hence, APPA 
interferes with threonine synthesis ultimately affecting 
protein synthesis and leading to growth inhibition 
(Borisova et al., 2010). Beside APPA based 
antibacterial compounds, some strains of B. subtilis 
produce the dipeptide bacilysin composed of L-alanine 
and the unusual amino acid L-anticapsin (Walker and 
Abraham, 1970). Anticapsin is able to inhibit 
glucosamine synthetize and thus causes a failure in the 
bacterial wall synthesis and finaly the growth of 




 The amazing biological properties of de different 
type of Bacillus’s compounds described in this review 
could be one answer to the multi-drug resistant 
concerns. To date, it is estimated that only a small 
fraction of the antimicrobial molecules potentially 
produced by Gram-positive bacteria has been identified. 
Research to discover these compounds is sure to be 




Abderrahmani, A., A. Tapi, F. Nateche, M. Chollet and 
V. Leclere et al., 2011. Bioinformatics and 
molecular approaches to detect NRPS genes 
involved in the biosynthesis of kurstakin from 
Bacillus thuringiensis. Applied Microbiol. 
Biotechnol., 92: 571-581. DOI: 10.1007/s00253-
011-3453-6 
Abriouel, H., C.M.A.P. Franz, N.B. Omar and A. 
Galvez, 2011. Diversity and applications of 
Bacillus bacteriocins. FEMS Microbiol. Rev., 35: 
201-232. DOI: 10.1111/j.1574-6976.2010.00244.x 
Ansari, M.Z., G. Yadav, R.S. Gokhale and D. Mohanty, 
2004. NRPS-PKS: A knowledge-based resource 
for analysis of NRPS/PKS megasynthases. Nucleic 
Acids Res., 32: W405-W413. DOI: 
10.1093/nar/gkh359 
Arguelles-Arias, A., M. Ongena, B. Halimi, Y. Lara 
and A. Brans et al., 2009. Bacillus 
amyloliquefaciens GA1 as a source of potent 
antibiotics and other secondary metabolites for 
biocontrol of plant pathogens. Microb. Cell Fact., 
8: 63-63. DOI: 10.1186/1475-2859-8-63 
Asaduzzaman, S.M. and S. Sonomoto, 2009. 
Lantibiotics: diverse activities and unique modes of 
action. J. Biosci. Bioeng., 107: 475-487. DOI: 
10.1016/j.jbiosc.2009.01.003 
Banerjee, S. and J.N. Hansen, 1988. Structure and 
expression of a gene encoding the precursor of 
subtilin, a small protein antibiotic. J. Biol. Chem., 
263: 9508-9514.  
Bierbaum, G. and H.G. Sahl, 2009. Lantibiotics: Mode 
of action, biosynthesis and bioengineering. Curr. 
Pharm. Biotechnol., 10: 2-18. DOI: 
10.2174/138920109787048616 
Borisova, S.A., B.T. Circello, J.K. Zhang, W.A.V.D. 
Donk and W.W. Metcalf, 2010. Biosynthesis of 
rhizocticins, antifungal phosphonate oligopeptides 
produced by Bacillus subtilis ATCC6633. Chem. 
Biol., 17: 28-37. DOI: 
10.1016/j.chembiol.2009.11.017 
Brotz, H. and H.G. Sahl, 2000. New insights into the 
mechanism of action of lantibiotics—diverse 
biological effects by binding to the same molecular 
target. J. Antimicrob. Chemother., 46: 1-6. DOI: 
10.1093/jac/46.1.1 
Caboche, S., M. Pupin, V. Leclere, A. Fontaine and P. 
Jacques et al., 2008. NORINE: A database of 
nonribosomal peptides. Nucl. Acids Res., 36: 
D326-D331. DOI: 10.1093/nar/gkm792 
Am. J. Biochem. & Biotech., 8 (1): 38-43, 2012 
 
42 
Cane, D.E., C.T. Walsh and C. Khosla, 1998. 
Harnessing the biosynthetic code: Combinations, 
permutations and mutations. Science, 282: 63-68. 
DOI: 10.1126/science.282.5386.63 
Chen, X.H., A. Koumoutsi, R. Scholz, A. Eisenreich 
and K. Schneider et al., 2007. Comparative 
analysis of the complete genome sequence of the 
plant growth–promoting bacterium Bacillus 
amyloliquefaciens FZB42. Nat. Biotechnol., 25: 
1007-1014. DOI: 10.1038/nbt1325 
Chen, X.H., A. Koumoutsi, R. Scholz and R. Borriss, 
2009a. More than Anticipated – Production of 
Antibiotics and Other Secondary Metabolites by 
Bacillus amyloliquefaciens FZB42. J. Mol. 
Microbiol. Biotechnol., 16: 14-24. DOI: 
10.1159/000142891 
Chen, X.H., A. Koumoutsi, R. Scholz, K. Schneider 
and J. Vater et al., 2009b. Genome analysis of 
Bacillus amyloliquefaciens FZB42 reveals its 
potential for biocontrol of plant pathogens. J. 
Biotechnol., 140: 27-37. DOI: 
10.1016/j.jbiotec.2008.10.011 
Diddens, H., M. Dorgerloh and H. Zahner, 1979. 
Metabolic products of microorganisms 176. On the 
transport of small peptide antibiotics in bacteria. J. 
Antibiot., 32: 87-90. DOI: 
10.7164/antibiotics.32.87 
Duitman, E.H., L.W. Hamoen, M. Rembold, G. 
Venema and H. Seitz et al., 1999. The 
mycosubtilin synthetase of Bacillus subtilis 
ATCC6633: A multifunctional hybrid between a 
peptide synthetase, an amino transferase and a fatty 
acid synthase. Proc. Natl. Acad. Sci. USA., 96: 
13294-13299. DOI: 10.1073/pnas.96.23.13294 
Felnagle, E.A., E.E. Jackson, Y.A. Chan, A.M. 
Podevels and A.D. Berti et al., 2008. 
Nonribosomal peptide synthetases involved in the 
production of medically relevant natural products. 
Mol. Pharm., 5: 191-211. DOI: 
10.1021/mp700137g 
Fickers, P., V. Leclere, J.S. Guez, M. Bechet and F. 
Coucheney et al., 2008. Temperature dependence 
of mycosubtilin homologue production in Bacillus 
subtilis ATCC6633. Res. Microbiol., 159: 449-457. 
DOI: 10.1016/j.resmic.2008.05.004 
Fickers, P., J.S. Guez, C. Damblon, V. Leclere and M. 
Béchet et al., 2009. High-Level Biosynthesis of the 
Anteiso-C17 Isoform of the Antibiotic 
Mycosubtilin in Bacillus subtilis and 
Characterization of Its Candidacidal Activity. 
Appl. Environ. Microbiol., 75: 4636-4640. DOI: 
10.1128/AEM.00548-09 
Gustafson, K.R., J.H. Cardellina, R.W. Fuller, O.S. 
Weislow and R.F. Kiser et al., 1989. AIDS-
antiviral sulfolipids from cyanobacteria (blue-green 
algae). J. Natl. Cancer Inst., 81: 1254-1258. DOI: 
10.1093/jnci/81.16.1254 
Hertweck, C., A. Luzhetskyy, Y. Rebets and A. 
Bechthold, 2007. Type II polyketide synthases: 
Gaining a deeper insight into enzymatic teamwork. 
Nat. Prod. Rep., 24: 162-90. DOI: 
10.1039/B507395M 
Hofemeister, J., B. Conrad, B. Adler, B. Hofemeister 
and J. Feesche et al., 2004. Genetic analysis of the 
biosynthesis of non-ribosomal peptide- and 
polyketide-like antibiotics, iron uptake and biofilm 
formation by Bacillus subtilis A1/3. Mol. Genet. 
Genomics., 272: 363-378. DOI: 10.1007/s00438-
004-1056-y 
Jenke-Kodama, H. and E. Dittmann, 2009. Evolution of 
metabolic diversity: Insights from microbial 
polyketide synthases. Phytochemistry, 70: 1858-
1868. DOI: 10.1016/j.phytochem.2009.05.021 
Kenig, M., E. Vandamme and E.P. Abraham, 1976. The 
Mode of Action of Bacilysin and Anticapsin and 
Biochemical Properties of Bacilysin-resistant 
Mutants. J. Gen. Microbiol., 94: 46-54. DOI: 
10.1099/00221287-94-1-46 
Kino, K., Y. Kotanaka, T. Arai and M. Yagasaki, 2009. 
A Novel L-amino acid ligase from bacillus subtilis 
NBRC3134, a microorganism producing peptide-
antibiotic rhizocticin. Biosci. Biotechnol. 
Biochem., 73: 901-907. DOI: 10.1271/bbb.80842 
Kino, K., 2010. Novel L-amino acid ligases catalyzing 
oligopeptide synthesis. Yakugaku Zasshi., 130: 
1463-1469. DOI: 10.1248/yakushi.130.1463  
Klaenhammer, T.R., 1993. Genetics of bacteriocins 
produced by lactic acid bacteria. FEMS Microbiol. 
Rev., 12: 39-85. DOI: 10.1111/j.1574-
6976.1993.tb00012.x 
Kleerebezem, M., R. Bongers, G. Rutten, W.D. Vos 
and O. Kuipers, 2004. Autoregulation of subtilin 
biosynthesis in Bacillus subtilis: The role of the 
spa-box in subtilin-responsive promoters. 
Peptides., 25: 1415-1424. DOI: 
10.1016/j.peptides.2003.11.025 
Kunst, F., N. Ogasawara, I. Moszer, A.M. Albertini and 
G. Alloni et al., 1997. The complete genome 
sequence of the gram-positive bacterium Bacillus 
subtilis. Nature, 390: 249-256. DOI: 
10.1038/36786 
Laber, B., K.P. Gerbling, C. Harde, K.H. Neff and E. 
Nordhoff et al., 1994. Mechanisms of interaction 
of Escherichia coli threonine synthase with 
substrates and inhibitors. Biochemistry, 33: 3413-
23. DOI: 10.1021/bi00177a035 
Lanen, S.G.V. and B. Chen, 2006. Microbial genomics 
for the improvement of natural product discovery. 
Curr. Opin. Microbiol., 9: 252-260. DOI: 
10.1016/j.mib.2006.04.002 
Am. J. Biochem. & Biotech., 8 (1): 38-43, 2012 
 
43 
Leclere, V., M. Bechet, A. Adam, J.S. Guez and B. 
Wathelet et al., 2005. Mycosubtilin overproduction 
by Bacillus subtilis BBG100 enhances the 
organism's antagonistic and biocontrol activities. 
Applied Environ. Microbiol., 71: 4577-4584. DOI: 
10.1128/AEM.71.8.4577-4584.2005 
Lee, H. and H. Kim, 2011. Lantibiotics, class I 
bacteriocins from the genus Bacillus. J. Microbiol. 
Biotechnol., 21: 229-235. PMID: 21464591  
Li, J., Y. Luo, J.K. Lee and H. Zhao, 2011. Cloning and 
characterization of a type III polyketide synthase 
from Aspergillus niger. Bioorg. Med. Chem. Lett., 
21: 6085-6089. DOI: 10.1016/j.bmcl.2011.08.058 
McAuliffe, O., R.P. Ross and C. Hill, 2001. 
Lantibiotics: Structure, biosynthesis and mode of 
action. FEMS Microbiol. Rev., 25: 285-308. DOI: 
10.1016/S0168-6445(00)00065-6 
Meurer, G., M. Gerlitz, E. Wendt-Pienkowski, L.C. 
Vining and J. Rohr et al., 1997. Iterative type II 
polyketide synthases, cyclases and ketoreductases 
exhibit context-dependent behavior in the 
biosynthesis of linear and angular decapolyketides. 
Chem. Biol., 4: 433-443. DOI: 10.1016/S1074-
5521(97)90195-2 
Mootz, H.D., D. Schwarzer and M.A. Marahiel, 2002. 
Ways of assembling complex natural products on 
modular nonribosomal peptide synthetases. Chem. 
Bio. Chem., 3: 490-504. DOI: 10.1002/1439-
7633(20020603)3:6<490::AID-
CBIC490>3.0.CO;2-N  
Nakano, C., H. Ozawa, G. Akanuma, N. Funa and S. 
Horinouchi, 2009. Biosynthesis of aliphatic 
polyketides by type III polyketide synthase and 
methyltransferase in Bacillus subtilis. J. Bacteriol., 
191: 4916-4923. DOI: 10.1128/JB.00407-09 
Nes, I.F. and J.R. Tagg, 1996. Novel lantibiotics and 
their pre-peptides. Ant. Van Leeuwenhoek, 69: 89-
97. DOI: 10.1007/BF00399414 
Parisot, J., S. Carey, E. Breukink, W.C. Chan and A. 
Narbad et al., 2008. Molecular mechanism of 
target recognition by subtilin, a class I lanthionine 
antibiotic. Antimicrob. Agent. Chemother., 52: 
612-618. DOI: 10.1128/AAC.00836-07 
Patel, P., S. Huang, S. Fisher, D. Pirnik and C. Aklonis 
et al., 1995. Bacillaene, a Novel Inhibitor of 
Procaryotic Protein Synthesis Produced by Bacillus 
subtilis: Production, taxonomy, isolation, physico-
chemical characterization and biological activity. J. 
Antibiot., 48: 997-1003. DOI: 
10.7164/antibiotics.48.997 
Resmi, M.S. and E.V. Soniya, 2012. Molecular cloning 
and differential expressions of two cDNA encoding 
Type III polyketide synthase in different tissues of 
Curcuma longa L. Gene, 491: 278-283. PMID: 
21986037 
Stein, T., S. Borchert, P. Kiesau, S. Heinzmann and S. 
Kloss et al., 2002. Dual control of subtilin 
biosynthesis and immunity in Bacillus subtilis. 
Mol. Microbiol., 44: 403-416. DOI: 
10.1046/j.1365-2958.2002.02869.x 
Stone, K.J. and J.L. Strominger, 1971. Mechanism of 
action of bacitracin: Complexation with metal ion 
and C55-Isoprenyl pyrophosphate. Proc. Natl. Acad. 
Sci. U SA., 68: 3223-3227. DOI: 
10.1073/pnas.68.12.3223 
Tabata, K., H. Ikeda and S.I. Hashimoto, 2005. ywfE in 
Bacillus subtilis codes for a novel enzyme, L-
amino acid ligase. J. Bacteriol., 187: 5195-5202. 
DOI: 10.1128/JB.187.15.5195-5202.2005 
Tapi, A., M. Chollet-Imbert, B. Scherens and P. 
Jacques, 2010. New approach for the detection of 
non-ribosomal peptide synthetase genes in Bacillus 
strains by polymerase chain reaction. Applied 
Microbiol. Biotechnol., 85: 1521-1531. DOI: 
10.1007/s00253-009-2176-4 
Tersch, M.A.V. and B.C. Carlton, 1984. Molecular 
cloning of structural and immunity genes for 
megacins A-216 and A-19213 in Bacillus 
megaterium. J. Bacteriol., 160: 854-859.  
Tsuge, K., T. Akiyama and M. Shoda, 2001. Cloning, 
Sequencing and characterization of the iturin a 
operon. J. Bacteriol., 183: 6265-6273. DOI: 
10.1128/JB.183.21.6265-6273.2001 
Walker, J.E. and E.P. Abraham, 1970. The structure of 
bacilysin and other products of Bacillus subtillis. 
Biochem. J., 118: 563-570. PMCID: PMC1179252 
Willey, J.M. and W.A.V.D. Donk, 2007. Lantibiotics: 
Peptides of diverse structure and function. Ann. 
Rev. Microbiol., 61: 477-501. DOI: 
10.1146/annurev.micro.61.080706.093501 
Wilson, K.E., J.E. Flor, R.E. Schwartz, H. Joshua and 
J.L. Smith et al., 1987. Difficidin and 
oxydifficidin: novel broad spectrum antibacterial 
antibiotics produced by bacillus subtilis II. 
isolation and physico-chemical characterization. J. 
Antibiot., 40: 1682-1691. DOI: 
10.7164/antibiotics.40.1682 
Zimmerman, S.B., C.D. Schwartz, R.L. Monaghan, 
B.A. Pelak and B. Weissberger et al., 1987. 
Difficidin and oxydifficidin: Novel broad spectrum 
antibacterial antibiotics produced by Bacillus 
subtilis. I. Production, taxonomy and antibacterial 
activity. J. Antibiot., 40: 1677-1681. DOI: 
10.7164/antibiotics.40.1677 
Zweerink, M.M. and A. Edison, 1987. Difficidin and 
oxydifficidin: novel broad spectrum antibacterial 
antibiotics produced by Bacillus subtilis. III. Mode 
of action of difficidin. J. Antibiot., 40: 1692-1697. 
DOI: 10.7164/antibiotics.40.1692 
